ESSA Pharma Inc (Nasdaq: EPIX), a clinical-stage pharmaceutical company that says it is focused on developing novel therapies for the treatment of prostate cancer, announced on Monday that it has completed an underwritten public offering of 4,830,918 of its common shares.
The shares are priced at USD27 per share before underwriting discounts. The company granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The total proceeds from the offering were around USD130m. The joint book-running managers for the offering are Jefferies and Piper Sandler, while lead manager for the offering is Oppenheimer & Co and Bloom Burton Securities Inc acted as co-manager for the offering.
The company aims to use the net proceeds from the offering to fund clinical activities, chemistry, manufacturing and controls, and research and development, working capital and general corporate purposes.
Metagenomi Adds Immuno-oncology Clinical Research Experts to its Scientific Advisory Board
Vividion Raises USD 135m in Series C Financing
NovellusDx Establishes Fore Biotherapeutics US as its Operating company in the United States
Dhingra Named Chairman of the Board of Directors at Lava Therapeutics
Bristol Myers Squibb announces cell therapy manufacturing facility construction
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
LARVOL names Mark Lagunowich as vice president, Global Sales
ESSA Pharma Inc completes underwritten public offering of common shares
ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market